OpenEvidence Raises $210M Series B at $3.5B Valuation as Medical AI Platform Serves 40% of U.S. Physicians
Summary
OpenEvidence secures $210M Series B funding at $3.5B valuation as its medical AI platform now serves over 40% of U.S. physicians daily across 10,000+ hospitals, handling 8.5 million clinical consultations monthly while launching DeepConsult™, the first AI agent designed specifically for autonomous medical research.
Key Points
- OpenEvidence raises $210 million Series B funding at $3.5 billion valuation, with Google Ventures and Kleiner Perkins co-leading the round and total funding exceeding $300 million since founding
- The medical AI platform now serves over 40% of U.S. physicians daily across 10,000+ hospitals, handling 8.5 million clinical consultations monthly and showing 2,000%+ year-over-year growth
- OpenEvidence launches DeepConsult™, the first AI agent built specifically for physicians that conducts autonomous medical research by analyzing hundreds of peer-reviewed studies in parallel